Skip to main content
Top
Published in: Molecular Cancer 1/2010

Open Access 01-12-2010 | Research

Inhibition of nuclear factor-kappa B differentially affects thyroid cancer cell growth, apoptosis, and invasion

Authors: Kevin T Bauerle, Rebecca E Schweppe, Bryan R Haugen

Published in: Molecular Cancer | Issue 1/2010

Login to get access

Abstract

Background

Nuclear factor-κB (NF-κB) is constitutively activated in many cancers and plays a key role in promoting cell proliferation, survival, and invasion. Our understanding of NF-κB signaling in thyroid cancer, however, is limited. In this study, we have investigated the role of NF-κB signaling in thyroid cancer cell proliferation, invasion, and apoptosis using selective genetic inhibition of NF-κB in advanced thyroid cancer cell lines.

Results

Three pharmacologic inhibitors of NF-κB differentially inhibited growth in a panel of advanced thyroid cancer cell lines, suggesting that these NF-κB inhibitors may have off-target effects. We therefore used a selective genetic approach to inhibit NF-κB signaling by overexpression of a dominant-negative IκBα (mIκBα). These studies revealed decreased cell growth in only one of five thyroid cancer cell lines (8505C), which occurred through a block in the S-G2/M transition. Resistance to TNFα-induced apoptosis was observed in all cell lines, likely through an NF-κB-dependent mechanism. Inhibition of NF-κB by mIκBα sensitized a subset of cell lines to TNFα-induced apoptosis. Sensitive cell lines displayed sustained activation of the stress-activated protein kinase/c-Jun NH2-terminal kinase (SAPK/JNK) pathway, defining a potential mechanism of response. Finally, NF-κB inhibition by mIκBα expression differentially reduced thyroid cancer cell invasion in these thyroid cancer cell lines. Sensitive cell lines demonstrated approximately a two-fold decrease in invasion, which was associated with differential expression of MMP-13. MMP-9 was reduced by mIκBα expression in all cell lines tested.

Conclusions

These data indicate that selective inhibition of NF-κB represents an attractive therapeutic target for the treatment of advanced thyroid. However, it is apparent that global regulation of thyroid cancer cell growth and invasion is not achieved by NF-κB signaling alone. Instead, our findings suggest that other important molecular processes play a critical role in defining the extent of NF-κB function within cancer cells.
Appendix
Available only for authorised users
Literature
1.
go back to reference Parker SL, Tong T, Bolden S, Wingo PA: Cancer statistics. CA Cancer J Clin. 1997, 47: 5-27. 10.3322/canjclin.47.1.5CrossRefPubMed Parker SL, Tong T, Bolden S, Wingo PA: Cancer statistics. CA Cancer J Clin. 1997, 47: 5-27. 10.3322/canjclin.47.1.5CrossRefPubMed
2.
go back to reference Haugen BR: Management of the patient with progressive radioiodine non-responsive disease. Semin Surg Oncol. 1999, 16: 34-41. 10.1002/(SICI)1098-2388(199901/02)16:1<34::AID-SSU7>3.0.CO;2-2CrossRefPubMed Haugen BR: Management of the patient with progressive radioiodine non-responsive disease. Semin Surg Oncol. 1999, 16: 34-41. 10.1002/(SICI)1098-2388(199901/02)16:1<34::AID-SSU7>3.0.CO;2-2CrossRefPubMed
3.
4.
go back to reference Pfister DG, Fagin JA: Refractory thyroid cancer: a paradigm shift in treatment is not far off. J Clin Oncol. 2008, 26: 4701-4704. 10.1200/JCO.2008.17.3682CrossRefPubMed Pfister DG, Fagin JA: Refractory thyroid cancer: a paradigm shift in treatment is not far off. J Clin Oncol. 2008, 26: 4701-4704. 10.1200/JCO.2008.17.3682CrossRefPubMed
5.
go back to reference Sherman SI: Molecularly targeted therapies for thyroid cancers. Endocr Pract. 2009, 15: 605-611. 10.4158/EP09131.RARCrossRefPubMed Sherman SI: Molecularly targeted therapies for thyroid cancers. Endocr Pract. 2009, 15: 605-611. 10.4158/EP09131.RARCrossRefPubMed
6.
go back to reference Pacifico F, Leonardi A: NF-kappaB in solid tumors. Biochem Pharmacol. 2006, 72: 1142-1152. 10.1016/j.bcp.2006.07.032CrossRefPubMed Pacifico F, Leonardi A: NF-kappaB in solid tumors. Biochem Pharmacol. 2006, 72: 1142-1152. 10.1016/j.bcp.2006.07.032CrossRefPubMed
7.
go back to reference Arsura M, Cavin LG: Nuclear factor-kappaB and liver carcinogenesis. Cancer Lett. 2005, 229: 157-169. 10.1016/j.canlet.2005.07.008CrossRefPubMed Arsura M, Cavin LG: Nuclear factor-kappaB and liver carcinogenesis. Cancer Lett. 2005, 229: 157-169. 10.1016/j.canlet.2005.07.008CrossRefPubMed
8.
go back to reference Liu J, Suresh Kumar KG, Yu D, Molton SA, McMahon M, Herlyn M, Thomas-Tikhonenko A, Fuchs SY: Oncogenic BRAF regulates beta-Trcp expression and NF-kappaB activity in human melanoma cells. Oncogene. 2007, 26: 1954-1958. 10.1038/sj.onc.1209994PubMedCentralCrossRefPubMed Liu J, Suresh Kumar KG, Yu D, Molton SA, McMahon M, Herlyn M, Thomas-Tikhonenko A, Fuchs SY: Oncogenic BRAF regulates beta-Trcp expression and NF-kappaB activity in human melanoma cells. Oncogene. 2007, 26: 1954-1958. 10.1038/sj.onc.1209994PubMedCentralCrossRefPubMed
9.
go back to reference Escarcega RO, Fuentes-Alexandro S, Garcia-Carrasco M, Gatica A, Zamora A: The transcription factor nuclear factor-kappa B and cancer. Clin Oncol (R Coll Radiol). 2007, 19: 154-161.CrossRef Escarcega RO, Fuentes-Alexandro S, Garcia-Carrasco M, Gatica A, Zamora A: The transcription factor nuclear factor-kappa B and cancer. Clin Oncol (R Coll Radiol). 2007, 19: 154-161.CrossRef
10.
go back to reference Brzoska K, Szumiel I: Signaling loops and linear pathways: NF-kappaB activation in response to genotoxic stress. Mutagenesis. 2009, 24: 1-8. 10.1093/mutage/gen056CrossRefPubMed Brzoska K, Szumiel I: Signaling loops and linear pathways: NF-kappaB activation in response to genotoxic stress. Mutagenesis. 2009, 24: 1-8. 10.1093/mutage/gen056CrossRefPubMed
11.
12.
go back to reference Karin M: Nuclear factor-kappaB in cancer development and progression. Nature. 2006, 441: 431-436. 10.1038/nature04870CrossRefPubMed Karin M: Nuclear factor-kappaB in cancer development and progression. Nature. 2006, 441: 431-436. 10.1038/nature04870CrossRefPubMed
13.
go back to reference Starenki DV, Namba H, Saenko VA, Ohtsuru A, Maeda S, Umezawa W, Yamashita S: Induction of thyroid cancer cell apoptosis by a novel nuclear factor kappaB inhibitor, dehydroxymethylepoxyquinomicin. Clin Cancer Res. 2004, 10: 6821-6829. 10.1158/1078-0432.CCR-04-0463CrossRefPubMed Starenki DV, Namba H, Saenko VA, Ohtsuru A, Maeda S, Umezawa W, Yamashita S: Induction of thyroid cancer cell apoptosis by a novel nuclear factor kappaB inhibitor, dehydroxymethylepoxyquinomicin. Clin Cancer Res. 2004, 10: 6821-6829. 10.1158/1078-0432.CCR-04-0463CrossRefPubMed
14.
go back to reference Meng Z, Mitsutake N, Nakashima M, Starenki D, Matsuse M, Takakura S, Namba H, Saenko V, Umezawa K, Ohtsuru A, Yamashita S: Dehydroxymethylepoxyquinomicin, a novel nuclear Factor-kappaB inhibitor, enhances antitumor activity of taxanes in anaplastic thyroid cancer cells. Endocrinology. 2008, 149: 5357-5365. 10.1210/en.2008-0279CrossRefPubMed Meng Z, Mitsutake N, Nakashima M, Starenki D, Matsuse M, Takakura S, Namba H, Saenko V, Umezawa K, Ohtsuru A, Yamashita S: Dehydroxymethylepoxyquinomicin, a novel nuclear Factor-kappaB inhibitor, enhances antitumor activity of taxanes in anaplastic thyroid cancer cells. Endocrinology. 2008, 149: 5357-5365. 10.1210/en.2008-0279CrossRefPubMed
15.
go back to reference Zhu W, Ou Y, Li Y, Xiao R, Shu M, Zhou Y, Xie J, He S, Qiu P, Yan G: A small-molecule triptolide suppresses angiogenesis and invasion of human anaplastic thyroid carcinoma cells via down-regulation of the nuclear factor-kappa B pathway. Mol Pharmacol. 2009, 75: 812-819. 10.1124/mol.108.052605CrossRefPubMed Zhu W, Ou Y, Li Y, Xiao R, Shu M, Zhou Y, Xie J, He S, Qiu P, Yan G: A small-molecule triptolide suppresses angiogenesis and invasion of human anaplastic thyroid carcinoma cells via down-regulation of the nuclear factor-kappa B pathway. Mol Pharmacol. 2009, 75: 812-819. 10.1124/mol.108.052605CrossRefPubMed
16.
go back to reference Mitsiades CS, McMillin D, Kotoula V, Poulaki V, McMullan C, Negri J, Fanourakis G, Tseleni-Balafouta S, Ain KB, Mitsiades N: Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro. J Clin Endocrinol Metab. 2006, 91: 4013-4021. 10.1210/jc.2005-2472CrossRefPubMed Mitsiades CS, McMillin D, Kotoula V, Poulaki V, McMullan C, Negri J, Fanourakis G, Tseleni-Balafouta S, Ain KB, Mitsiades N: Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro. J Clin Endocrinol Metab. 2006, 91: 4013-4021. 10.1210/jc.2005-2472CrossRefPubMed
17.
go back to reference Liu D, Xing M: Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kappaB pathways. Thyroid. 2008, 18: 853-864. 10.1089/thy.2007.0357PubMedCentralCrossRefPubMed Liu D, Xing M: Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kappaB pathways. Thyroid. 2008, 18: 853-864. 10.1089/thy.2007.0357PubMedCentralCrossRefPubMed
18.
go back to reference Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow LA, Copland JA, Smallridge RC, Haugen BR: Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab. 2008, 93: 4331-4341. 10.1210/jc.2008-1102PubMedCentralCrossRefPubMed Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow LA, Copland JA, Smallridge RC, Haugen BR: Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab. 2008, 93: 4331-4341. 10.1210/jc.2008-1102PubMedCentralCrossRefPubMed
19.
go back to reference Karin M, Yamamoto Y, Wang QM: The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov. 2004, 3: 17-26. 10.1038/nrd1279CrossRefPubMed Karin M, Yamamoto Y, Wang QM: The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov. 2004, 3: 17-26. 10.1038/nrd1279CrossRefPubMed
20.
go back to reference Li B, Li YY, Tsao SW, Cheung AL: Targeting NF-kappaB signaling pathway suppresses tumor growth, angiogenesis, and metastasis of human esophageal cancer. Mol Cancer Ther. 2009, 8: 2635-2644. 10.1158/1535-7163.MCT-09-0162CrossRefPubMed Li B, Li YY, Tsao SW, Cheung AL: Targeting NF-kappaB signaling pathway suppresses tumor growth, angiogenesis, and metastasis of human esophageal cancer. Mol Cancer Ther. 2009, 8: 2635-2644. 10.1158/1535-7163.MCT-09-0162CrossRefPubMed
21.
go back to reference Shishodia S, Sethi G, Konopleva M, Andreeff M, Aggarwal BB: A synthetic triterpenoid, CDDO-Me, inhibits IkappaBalpha kinase and enhances apoptosis induced by TNF and chemotherapeutic agents through down-regulation of expression of nuclear factor kappaB-regulated gene products in human leukemic cells. Clin Cancer Res. 2006, 12: 1828-1838. 10.1158/1078-0432.CCR-05-2044CrossRefPubMed Shishodia S, Sethi G, Konopleva M, Andreeff M, Aggarwal BB: A synthetic triterpenoid, CDDO-Me, inhibits IkappaBalpha kinase and enhances apoptosis induced by TNF and chemotherapeutic agents through down-regulation of expression of nuclear factor kappaB-regulated gene products in human leukemic cells. Clin Cancer Res. 2006, 12: 1828-1838. 10.1158/1078-0432.CCR-05-2044CrossRefPubMed
22.
go back to reference Deeb D, Gao X, Dulchavsky SA, Gautam SC: CDDO-me induces apoptosis and inhibits Akt, mTOR and NF-kappaB signaling proteins in prostate cancer cells. Anticancer Res. 2007, 27: 3035-3044.PubMed Deeb D, Gao X, Dulchavsky SA, Gautam SC: CDDO-me induces apoptosis and inhibits Akt, mTOR and NF-kappaB signaling proteins in prostate cancer cells. Anticancer Res. 2007, 27: 3035-3044.PubMed
23.
go back to reference Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM: Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science. 1996, 274: 787-789. 10.1126/science.274.5288.787CrossRefPubMed Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM: Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science. 1996, 274: 787-789. 10.1126/science.274.5288.787CrossRefPubMed
24.
go back to reference Van Antwerp DJ, Verma IM: Signal-induced degradation of I(kappa)B(alpha): association with NF-kappaB and the PEST sequence in I(kappa)B(alpha) are not required. Mol Cell Biol. 1996, 16: 6037-6045.PubMedCentralCrossRefPubMed Van Antwerp DJ, Verma IM: Signal-induced degradation of I(kappa)B(alpha): association with NF-kappaB and the PEST sequence in I(kappa)B(alpha) are not required. Mol Cell Biol. 1996, 16: 6037-6045.PubMedCentralCrossRefPubMed
25.
go back to reference Wan YY, DeGregori J: The survival of antigen-stimulated T cells requires NFkappaB-mediated inhibition of p73 expression. Immunity. 2003, 18: 331-342. 10.1016/S1074-7613(03)00053-0CrossRefPubMed Wan YY, DeGregori J: The survival of antigen-stimulated T cells requires NFkappaB-mediated inhibition of p73 expression. Immunity. 2003, 18: 331-342. 10.1016/S1074-7613(03)00053-0CrossRefPubMed
26.
go back to reference Luo JL, Kamata H, Karin M: IKK/NF-kappaB signaling: balancing life and death--a new approach to cancer therapy. J Clin Invest. 2005, 115: 2625-2632. 10.1172/JCI26322PubMedCentralCrossRefPubMed Luo JL, Kamata H, Karin M: IKK/NF-kappaB signaling: balancing life and death--a new approach to cancer therapy. J Clin Invest. 2005, 115: 2625-2632. 10.1172/JCI26322PubMedCentralCrossRefPubMed
27.
go back to reference Hanahan D, Weinberg RA: The hallmarks of cancer. Cell. 2000, 100: 57-70. 10.1016/S0092-8674(00)81683-9CrossRefPubMed Hanahan D, Weinberg RA: The hallmarks of cancer. Cell. 2000, 100: 57-70. 10.1016/S0092-8674(00)81683-9CrossRefPubMed
28.
go back to reference Pacifico F, Mauro C, Barone C, Crescenzi E, Mellone S, Monaco M, Chiappetta G, Terrazzano G, Liguoro D, Vito P: Oncogenic and anti-apoptotic activity of NF-kappa B in human thyroid carcinomas. J Biol Chem. 2004, 279: 54610-54619. 10.1074/jbc.M403492200CrossRefPubMed Pacifico F, Mauro C, Barone C, Crescenzi E, Mellone S, Monaco M, Chiappetta G, Terrazzano G, Liguoro D, Vito P: Oncogenic and anti-apoptotic activity of NF-kappa B in human thyroid carcinomas. J Biol Chem. 2004, 279: 54610-54619. 10.1074/jbc.M403492200CrossRefPubMed
29.
30.
go back to reference Flatt PM, Tang LJ, Scatena CD, Szak ST, Pietenpol JA: p53 regulation of G(2) checkpoint is retinoblastoma protein dependent. Mol Cell Biol. 2000, 20: 4210-4223. 10.1128/MCB.20.12.4210-4223.2000PubMedCentralCrossRefPubMed Flatt PM, Tang LJ, Scatena CD, Szak ST, Pietenpol JA: p53 regulation of G(2) checkpoint is retinoblastoma protein dependent. Mol Cell Biol. 2000, 20: 4210-4223. 10.1128/MCB.20.12.4210-4223.2000PubMedCentralCrossRefPubMed
31.
go back to reference Xiao M, Inal CE, Parekh VI, Li XH, Whitnall MH: Role of NF-kappaB in hematopoietic niche function of osteoblasts after radiation injury. Exp Hematol. 2009, 37: 52-64. 10.1016/j.exphem.2008.09.001CrossRefPubMed Xiao M, Inal CE, Parekh VI, Li XH, Whitnall MH: Role of NF-kappaB in hematopoietic niche function of osteoblasts after radiation injury. Exp Hematol. 2009, 37: 52-64. 10.1016/j.exphem.2008.09.001CrossRefPubMed
32.
go back to reference Han SW, Roman J: Fibronectin induces cell proliferation and inhibits apoptosis in human bronchial epithelial cells: pro-oncogenic effects mediated by PI3-kinase and NF-kappa B. Oncogene. 2006, 25: 4341-4349. 10.1038/sj.onc.1209460CrossRefPubMed Han SW, Roman J: Fibronectin induces cell proliferation and inhibits apoptosis in human bronchial epithelial cells: pro-oncogenic effects mediated by PI3-kinase and NF-kappa B. Oncogene. 2006, 25: 4341-4349. 10.1038/sj.onc.1209460CrossRefPubMed
33.
go back to reference Raffoul JJ, Wang Y, Kucuk O, Forman JD, Sarkar FH, Hillman GG: Genistein inhibits radiation-induced activation of NF-kappaB in prostate cancer cells promoting apoptosis and G2/M cell cycle arrest. BMC Cancer. 2006, 6: 107- 10.1186/1471-2407-6-107PubMedCentralCrossRefPubMed Raffoul JJ, Wang Y, Kucuk O, Forman JD, Sarkar FH, Hillman GG: Genistein inhibits radiation-induced activation of NF-kappaB in prostate cancer cells promoting apoptosis and G2/M cell cycle arrest. BMC Cancer. 2006, 6: 107- 10.1186/1471-2407-6-107PubMedCentralCrossRefPubMed
34.
go back to reference Palona I, Namba H, Mitsutake N, Starenki D, Podtcheko A, Sedliarou I, Ohtsuru A, Saenko V, Nagayama Y, Umezawa K, Yamashita S: BRAFV600E promotes invasiveness of thyroid cancer cells through nuclear factor kappaB activation. Endocrinology. 2006, 147: 5699-5707. 10.1210/en.2006-0400CrossRefPubMed Palona I, Namba H, Mitsutake N, Starenki D, Podtcheko A, Sedliarou I, Ohtsuru A, Saenko V, Nagayama Y, Umezawa K, Yamashita S: BRAFV600E promotes invasiveness of thyroid cancer cells through nuclear factor kappaB activation. Endocrinology. 2006, 147: 5699-5707. 10.1210/en.2006-0400CrossRefPubMed
35.
go back to reference Papenfuss K, Cordier SM, Walczakya H: Death receptors as targets for anti-cancer therapy. J Cell Mol Med. 2008, 12: 2566-2585. 10.1111/j.1582-4934.2008.00514.xPubMedCentralCrossRefPubMed Papenfuss K, Cordier SM, Walczakya H: Death receptors as targets for anti-cancer therapy. J Cell Mol Med. 2008, 12: 2566-2585. 10.1111/j.1582-4934.2008.00514.xPubMedCentralCrossRefPubMed
36.
go back to reference Papa S, Zazzeroni F, Pham CG, Bubici C, Franzoso G: Linking JNK signaling to NF-kappaB: a key to survival. J Cell Sci. 2004, 117: 5197-5208. 10.1242/jcs.01483CrossRefPubMed Papa S, Zazzeroni F, Pham CG, Bubici C, Franzoso G: Linking JNK signaling to NF-kappaB: a key to survival. J Cell Sci. 2004, 117: 5197-5208. 10.1242/jcs.01483CrossRefPubMed
37.
go back to reference Tang F, Tang G, Xiang G, Dai Q, Rosner MR, Lin A: The absence of NF-kappaB-mediated inhibition of c-Jun N-terminal kinase activation contributes to tumor necrosis factor alpha-induced apoptosis. Mol Cell Biol. 2002, 22: 8571-8579. 10.1128/MCB.22.24.8571-8579.2002PubMedCentralCrossRefPubMed Tang F, Tang G, Xiang G, Dai Q, Rosner MR, Lin A: The absence of NF-kappaB-mediated inhibition of c-Jun N-terminal kinase activation contributes to tumor necrosis factor alpha-induced apoptosis. Mol Cell Biol. 2002, 22: 8571-8579. 10.1128/MCB.22.24.8571-8579.2002PubMedCentralCrossRefPubMed
38.
39.
go back to reference Noutomi T, Itoh M, Toyota H, Takada E, Mizuguchi J: Tumor necrosis factor-related apoptosis-inducing ligand induces apoptotic cell death through c-Jun NH2-terminal kinase activation in squamous cell carcinoma cells. Oncol Rep. 2009, 22: 1169-1172.PubMed Noutomi T, Itoh M, Toyota H, Takada E, Mizuguchi J: Tumor necrosis factor-related apoptosis-inducing ligand induces apoptotic cell death through c-Jun NH2-terminal kinase activation in squamous cell carcinoma cells. Oncol Rep. 2009, 22: 1169-1172.PubMed
40.
go back to reference Stamenkovic I: Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol. 2000, 10: 415-433. 10.1006/scbi.2000.0379CrossRefPubMed Stamenkovic I: Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol. 2000, 10: 415-433. 10.1006/scbi.2000.0379CrossRefPubMed
41.
go back to reference Min C, Eddy SF, Sherr DH, Sonenshein GE: NF-kappaB and epithelial to mesenchymal transition of cancer. J Cell Biochem. 2008, 104: 733-744. 10.1002/jcb.21695CrossRefPubMed Min C, Eddy SF, Sherr DH, Sonenshein GE: NF-kappaB and epithelial to mesenchymal transition of cancer. J Cell Biochem. 2008, 104: 733-744. 10.1002/jcb.21695CrossRefPubMed
42.
go back to reference Baldini E, Toller M, Graziano FM, Russo FP, Pepe M, Biordi L, Marchioni E, Curcio F, Ulisse S, Ambesi-Impiombato FS, D'Armiento M: Expression of matrix metalloproteinases and their specific inhibitors in normal and different human thyroid tumor cell lines. Thyroid. 2004, 14: 881-888. 10.1089/thy.2004.14.881CrossRefPubMed Baldini E, Toller M, Graziano FM, Russo FP, Pepe M, Biordi L, Marchioni E, Curcio F, Ulisse S, Ambesi-Impiombato FS, D'Armiento M: Expression of matrix metalloproteinases and their specific inhibitors in normal and different human thyroid tumor cell lines. Thyroid. 2004, 14: 881-888. 10.1089/thy.2004.14.881CrossRefPubMed
43.
go back to reference Duriez PJ, Shah GM: Cleavage of poly(ADP-ribose) polymerase: a sensitive parameter to study cell death. Biochem Cell Biol. 1997, 75: 337-349. 10.1139/bcb-75-4-337CrossRefPubMed Duriez PJ, Shah GM: Cleavage of poly(ADP-ribose) polymerase: a sensitive parameter to study cell death. Biochem Cell Biol. 1997, 75: 337-349. 10.1139/bcb-75-4-337CrossRefPubMed
Metadata
Title
Inhibition of nuclear factor-kappa B differentially affects thyroid cancer cell growth, apoptosis, and invasion
Authors
Kevin T Bauerle
Rebecca E Schweppe
Bryan R Haugen
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2010
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-9-117

Other articles of this Issue 1/2010

Molecular Cancer 1/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine